Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087213 | 1.00 | TDP1 (0.54) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL16802865 | 0.90 | TDP1 (0.52) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL12094065 | 0.89 | TDP1 (0.67) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL13255781 | 0.88 | TDP1 (0.51) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL14686224 | 0.88 | TDP1 (0.51) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL359304 | 0.88 | TDP1 (0.55) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL2580946 | 0.88 | TDP1 (0.55) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL2579133 | 0.88 | TDP1 (0.55) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL18214049 | 0.87 | TDP1 (0.52) | TDP1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL24119147 | 0.86 | TDP1 (0.54) | TDP1MEN1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440853-B2 | Ester compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20120322870-A1 | ESTER COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322870-A1 | ESTER COMPOUND AND USE THEREOF | C9, CASP4, C1S | TDP1 4015/4885MEN1 269/4885KMT2A 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.